Regeneron Sustainability Profile
Regeneron Pharmaceuticals, Inc., commonly referred to as Regeneron, is a leading biotechnology company headquartered in the United States. Founded in 1988, Regeneron has established itself as a pioneer in the development of innovative medicines, particularly in the fields of ophthalmology, oncology, and immunology. With a strong focus on research and development, Regeneron is renowned for its unique products, including EYLEA® for eye diseases and Dupixent® for various allergic conditions. The company’s commitment to scientific excellence has positioned it as a key player in the biopharmaceutical industry, achieving significant milestones such as the rapid development of treatments during public health emergencies. Regeneron continues to expand its global footprint, with major operations across North America and Europe, solidifying its reputation as a leader in advancing healthcare solutions.
DitchCarbon Score
How does Regeneron's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Regeneron's score of 54 is higher than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Regeneron's reported carbon emissions
In 2024, Regeneron Pharmaceuticals, Inc. reported total greenhouse gas emissions of approximately 1,465,520,000 kg CO2e. This figure includes Scope 1 emissions of about 80,300,000 kg CO2e, Scope 2 emissions of approximately 40,400,000 kg CO2e (market-based), and significant Scope 3 emissions totalling around 1,344,820,000 kg CO2e. The combined Scope 1 and 2 emissions amounted to about 120,700,000 kg CO2e (market-based). For 2023, the company recorded total emissions of approximately 972,376,000 kg CO2e, with Scope 1 emissions at about 69,600,000 kg CO2e, Scope 2 emissions of approximately 29,900,000 kg CO2e (market-based), and Scope 3 emissions reaching around 872,876,000 kg CO2e. Regeneron has set ambitious reduction targets, aiming to decrease its combined Scope 1 and 2 greenhouse gas emissions per square meter by 30% by 2025, using a 2016 peak baseline. This target applies to both Scope 1 and Scope 2 emissions. Additionally, the company plans to match 100% of its electricity consumption with certified renewable energy sources by 2035, encompassing both Scope 1 and Scope 2 emissions. The emissions data and reduction initiatives are sourced directly from Regeneron Pharmaceuticals, Inc., with no cascaded data from parent or related organizations.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 39,400,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 25,300,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 288,800,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 0,000,000,000 |
How Carbon Intensive is Regeneron's Industry?
How Carbon Intensive is Regeneron's Location?
Regeneron's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Regeneron has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
